Trial · NCT01189890
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30 | Sitagliptin | -0.32 | 95% Confidence Interval 0.78 | Percentage of HbA1c | |
| Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30 | Glimepiride | -0.51 | 95% Confidence Interval 0.89 | Percentage of HbA1c | |
| Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30 | Sitagliptin | 2 | Participants | ||
| Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30 | Glimepiride | 11 | Participants | ||
| Number of Participants Experiencing An Adverse Event (AE) | Sitagliptin | 118 | Participants | ||
| Number of Participants Experiencing An Adverse Event (AE) | Glimepiride | 115 | Participants | ||
| Number of Participants Discontinuing Study Treatment Due to An AE | Sitagliptin | 3 | Participants | ||
| Number of Participants Discontinuing Study Treatment Due to An AE | Glimepiride | 4 | Participants | ||
| LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30 | Sitagliptin | -14.5 | 95% Confidence Interval 39.0 | mg/dL | |
| LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30 | Glimepiride | -21.2 | 95% Confidence Interval 39.1 | mg/dL | |
| Percentage of Participants With HbA1c <7.0% at Week 30 | Sitagliptin | 33.5 | Percentage of Participants | ||
| Percentage of Participants With HbA1c <7.0% at Week 30 | Glimepiride | 46.6 | Percentage of Participants | ||
| Percentage of Participants With HbA1c <6.5% at Week 30 | Sitagliptin | 9.1 | Percentage of Participants | ||
| Percentage of Participants With HbA1c <6.5% at Week 30 | Glimepiride | 20.9 | Percentage of Participants | ||
| LS Mean Change From Baseline in Participant Body Weight at Week 30 | Sitagliptin | 0.4 | 95% Confidence Interval 3.2 | kg | |
| LS Mean Change From Baseline in Participant Body Weight at Week 30 | Glimepiride | 1.1 | 95% Confidence Interval 2.8 | kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01189890/results